Company Overview
ASP Isotopes Inc. operates as a development stage advanced materials company focused on the production, distribution, marketing, and sale of isotopes through its Nuclear Fuels and Specialist Isotopes and Related Services segments. The company is classified within the Basic Materials sector and the Chemicals industry, positioning it as a provider of specialized chemical inputs often utilized in industrial, medical, or research applications. With a market capitalization of $623.05M, an annual revenue of $8.38M, and an employee count of 136, the firm presents a profile of a mid-sized entity with significant operational scope relative to its current revenue stream. The disparity between the $623.05M market cap and the $8.38M revenue indicates that the market is valuing the company based on future growth potential, technological assets, or strategic positioning rather than current earnings performance, which is typical for development stage companies in the advanced materials space.
Financial Health
The company reported revenue of $8.38M over the trailing twelve months, accompanied by a net income of -$105,564,392 and an EBITDA of -$41,514,560. The substantial gap between the $8.38M revenue and the -$105,564,392 net income reveals a highly aggressive cost structure where operating expenses, including research and development or administrative costs, far exceed total revenue generation. Free cash flow stands at -$67,549,232, indicating that the company is currently burning cash to fund operations and expansion, which limits immediate financial flexibility but may be necessary for a development stage business aiming to achieve commercial scale. Margins reflect this intense operational pressure, with a gross margin of 23.0%, an operating margin of -306.1%, and a profit margin of 0.0%, suggesting that while the core product sales retain some value, overhead costs are so high they completely erode operating profitability. The balance sheet shows $114.04M in cash against $113.66M in debt, resulting in a debt-to-equity ratio of 117.65, which characterizes a highly leveraged position where debt obligations nearly match available liquid assets. Despite the high leverage, the current ratio of 6.14 suggests strong short-term liquidity, as the company holds significantly more current assets than current liabilities, providing a buffer to meet immediate obligations. Return on Equity is -152.6% and Return on Assets is -17.2%, metrics that indicate management is currently unable to generate positive returns on the capital invested or the assets utilized, a common characteristic for firms in early development phases that have not yet reached profitability.
Valuation Assessment
Valuation metrics for ASP Isotopes Inc. are constrained by its lack of earnings, resulting in a P/E Ratio (TTM) of N/A and a Forward P/E of -6.92. The negative forward P/E implies that the market is not pricing in immediate earnings recovery but rather relying on other valuation drivers or expecting a turnaround in profitability. The Price to Book ratio is 6.28, indicating that the market values the company at more than six times its book value, which suggests a significant premium assigned to its intangible assets, intellectual property, or future growth prospects despite current losses. Alternative valuation multiples provide further context, with a Price to Sales ratio of 74.32 and an EV/EBITDA of -13.83, both of which highlight that the stock is priced heavily on revenue expectations rather than cash flow generation or earnings power. Price metrics show a 52-Week High of $14.49 and a 52-Week Low of $3.92, meaning the stock is trading within a range that reflects high volatility and significant potential for price swings based on sector sentiment or specific news. The Beta of 3.57 indicates that the stock price is highly volatile and moves with roughly 3.5 times the magnitude of the broader market, making it a speculative investment suitable only for investors with a high tolerance for risk.
Growth & Income
Revenue growth over the last year stands at 349.5%, while earnings growth is N/A due to the company's continued net losses. The fact that earnings growth is unavailable while revenue grows at such a rapid pace implies that the company is expanding its top line but has not yet converted that revenue into net income, suggesting ongoing heavy investment in operations before achieving profitability. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that it retains all earnings to reinvest into its growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is typical for development stage companies that prioritize expanding market share and developing new isotopes over returning capital to investors. Overall, the company presents a growth-oriented profile characterized by rapid revenue expansion but lacks an income component, relying entirely on capital markets and existing cash reserves to fund its aggressive growth trajectory.